NCT04008797 2026-02-27
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
Eisai Inc.
Helix BioPharma Corporation
GI Innovation, Inc.
Swiss Cancer Institute
University of British Columbia